Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPY2R | P49146 | 3/20 | 0.46 |
| ▸ | TOP2A | P11388 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.45 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 1/20 | 0.45 |
| ▸ | SKP1 | P63208 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1481365 | 0.95 | MEN1 (0.59) | MEN1KMT2ASMN1; SMN2HTTNPSR1 | |
| SCHEMBL20516395 | 0.90 | MEN1 (0.54) | MEN1KMT2ASMN1; SMN2HTTNPSR1 | |
| SCHEMBL20339474 | 0.88 | GPR119 (0.55) | MEN1KMT2ASMN1; SMN2HTTNPSR1 | |
| SCHEMBL10306695 | 0.87 | KMT2A (0.52) | MEN1KMT2ASMN1; SMN2HTTNPSR1 | |
| SCHEMBL29902983 | 0.87 | KMT2A (0.52) | MEN1KMT2ASMN1; SMN2HTTNPSR1 | |
| SCHEMBL532058 | 0.87 | POLB (0.49) | MEN1KMT2ASMN1; SMN2HTTNPSR1 | |
| SCHEMBL20339473 | 0.86 | SMN1; SMN2 (0.52) | MEN1KMT2ASMN1; SMN2HTTNPSR1 | |
| SCHEMBL30858329 | 0.86 | L3MBTL1 (0.59) | MEN1KMT2ASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL354715 | 0.86 | L3MBTL1 (0.59) | MEN1KMT2ASMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL355161 | 0.86 | LMNA (0.53) | MEN1KMT2ASMN1; SMN2HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993585-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | MITOBRIDGE, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| WO-2024043242-A1 | HEART FAILURE TREATMENT VIA CARDIOTONIC EFFECT BY TRPC3/6/7 CHANNEL ACTIVATION | 国立大学法人九州大学 | 2024-02-29 | — | — | WO | disclosed |
| CN-110167926-B | Poly-ADP ribose polymerase (PARP) inhibitors | 米托布里奇公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20220033380-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2022-02-03 | — | — | US | disclosed |
| US-11034670-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | MITOBRIDGE, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3562822-B1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | MITOBRIDGE INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-20200071299-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2020-03-05 | — | — | US | disclosed |
| US-10336709-B2 | Lp-PLA2 inhibitors | ABIDE THERAPEUTICS, INC (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336709-B2 | Lp-PLA2 inhibitors | ABIDE THERAPEUTICS, INC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180282288-A1 | LP-PLA2 INHIBITORS | H. LUNDBECK A/S (DK) | 2018-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033380-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP11 | MEN1 3731/4885KMT2A 1583/4885SMN1; SMN2 945/4885 |
| US-11993585-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | PARP1, PARP2, PARP11 | MEN1 3731/4885KMT2A 1583/4885SMN1; SMN2 945/4885 |
| US-20180282288-A1 | LP-PLA2 INHIBITORS | PLA2G12A, PLA2G12B, PLA2G4B | MEN1 3915/4885KMT2A 1911/4885SMN1; SMN2 2835/4885 |
| US-11034670-B2 | Poly-ADP ribose polymerase (PARP) inhibitors | PARP1, PARP2, PARP11 | MEN1 3731/4885KMT2A 1583/4885SMN1; SMN2 945/4885 |
| US-20200071299-A1 | POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP11 | MEN1 3731/4885KMT2A 1583/4885SMN1; SMN2 945/4885 |
| US-10336709-B2 | Lp-PLA2 inhibitors | PLA2G12A, PLA2G12B, PLA2G1B | MEN1 3860/4885KMT2A 1803/4885SMN1; SMN2 2507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.